Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

SAN FRANCISCO, Nov. 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today presented data from its phase 2 clinical trial of XL784 in subjects with albuminuria due to diabetic nephropathy. XL784 is a small molecule inhibitor of ADAM-10 and MMP-2, metalloprotease enzymes that may play a role in the pathogenesis of diabetic nephropathy and renal fibrosis. The data were presented during a poster session (Abstract/Poster PO1030) at the American Society of Nephrology Renal Week 2007 meeting in San Francisco. The company previously announced that the clinical trial did not meet its primary endpoint.

125 subjects were enrolled into this randomized, double-blind, placebo-controlled study. XL784 (200mg once daily for 12 weeks) was compared to placebo in subjects with macro-albuminuria who were being treated concurrently with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB).

The primary endpoint was the reduction from baseline in the urinary albumin to creatinine ratio (ACR) at Week 12. Proteinuria, the presence of excess protein in the urine, is an indicator of renal disease. Albumin excretion is a risk factor for kidney failure, stroke and cardiovascular and all-cause mortality, particularly in patients with diabetes and/or hypertension. Nephropathy (kidney disease) is a common problem in diabetic patients, often leading to the need for hemodialysis or kidney transplant.

After 12 weeks of treatment with XL784 the baseline normalized ACR (end of treatment/baseline ACR) in the XL784 group was 9.9% lower than that in the placebo group (not significant). There was a clinically relevant mean ACR reduction from baseline of 23% (p=0.0027) in subjects randomized to XL784. The change in glomerular filtration rate (GFR) at Week 12 was -2.5 ml/min/1.73m2 in the XL784 group and -6.2 ml/min/1.73m2 in the placebo group (p=0.077).

In an exploratory analysis, subjects were stratified according to dose of ACEi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... HILL, Conn. , July 2, 2015 ... Chief Executive Officer announced that Tamas Feitel ... Feitel joins Numotion after a highly successful 18 ... finance leadership roles driving strategy, profitability, and productivity to ... His most recent position was Chief Financial Officer for ...
(Date:7/2/2015)... and DURHAM, N.C. , July 2, ... announced its acquisition of assets related to the ion ... ) that had previously been obtained as part of ... acquired all of Pfizer,s rights to the "Icagen" name ... and will provide comprehensive services for ion channel and ...
(Date:7/2/2015)...  Konica Minolta, Inc. (Konica Minolta) ( Tokyo ... Sawae Technologica Ltda., an X-ray system equipment manufacturer based ... its Brazilian healthcare sales company, Konica Minolta Healthcare do ... Brazil market investment and growth With ... million, significant healthcare technical advancements and efficiencies are required. ...
Breaking Medicine Technology:Numotion Names Tamas Feitel Chief Financial Officer 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 2Konica Minolta Acquires Sawae, Enhancing Digital X-ray Diagnostic Imaging Systems in Brazil 3
... Aesthetic Plastic,Surgery,s Annual Meeting, NEW YORK, May ... nonsurgical cosmetic enhancement are being introduced at a,rapid ... they promise? Are,the results of minimally invasive treatments, ... to more extensive procedures? Are these,new modalities safe ...
... -Memory Receives $6 Million Milestone Payment- ... at 9:00 a.m. EDT Today-, MONTVALE, N.J. and ... MEMY ) and Roche (SWX: ROG) today,announced that Roche ... Pharmaceuticals, lead nicotinic alpha-7 agonist drug,candidate, MEM 3454, for ...
Cached Medicine Technology:Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures 2Got Fat?: Plastic Surgeons Review Fat-Melting and Fat-Grafting Procedures 3Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 2Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 3Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 4
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the ... members of the Red Deer community with free fitness training and indoor fitness boot ... food, events and entertainment raised thousands of charity dollars and ended with a $10,000 ...
(Date:7/2/2015)... ... ... Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, Texas. ... premium frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest ... Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , ...
(Date:7/2/2015)... ... 02, 2015 , ... The American Association of Poison Control ... Overdose Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with the ... decrease drug overdose – especially of heroin and opioid medication – by expanding ...
(Date:7/2/2015)... ... ... in full swing, Americans are flocking to Canada’s many lakes to reel in their fair ... world, and it’s easy to understand why. From the Pacific Northwest Coast of British Columbia ... is a huge industry, and Americans make up the vast majority of anglers from outside ...
(Date:7/2/2015)... ... July 02, 2015 , ... As Americans celebrate the Fourth ... temps, skin cancer is on the rise. July is UV Safety Month, and physicians ... about the importance of getting skin checks. Experts say most skin cancers can be ...
Breaking Medicine News(10 mins):Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... PEMBROKE, Bermuda, Sept. 21 Allied World,Assurance Company Holdings, ... AVP, Risk Management for Allied World U.S., will be speaking ... Ohio Association of,Ambulatory Surgery Centers (OAASC) annual meeting at the ... Ms. McSmith,s presentation, "How Much Risk ...
... of their ability to survive too long and multiply too ... journal Experimental Hematology . To function normally, the ... divide and multiply (proliferate) and when to die. Cell death ... and billions of cells must die each year just to ...
... Scientists have ample evidence that individuals use a variety of ... resemblances in families other than their own. A new study ... whether or not those families are the same race as ... Journal of Vision ("Cross-cultural perceptions of facial resemblance ...
... INDIANAPOLIS, Sept. 21 Eli Lilly and Company ... on the Human Rights Campaign,s (HRC) Corporate Equality Index for 2010. ... the Best Places to Work for Lesbian, Gay, Bisexual, and Transgender (LGBT) ... organization,s efforts related to creating an equitable environment for lesbian, gay, bisexual, ...
... BOSTON, Sept. 21 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... new purchase orders for its MammoView(TM) line of surgical endoscopy ... their client base over the last 12 months. More than ... affiliated with prestigious public and private Universities across the Country. ...
... , , , ... Partners, LLC has discovered new prior art impacting the validity ... communications devices. Article One also announced the discovery of new ... Cymbalta to be invalid, as verified by outside counsel. The ...
Cached Medicine News:Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 2Health News:Allied World's Linda McSmith to Speak at Ohio Association of Ambulatory Surgery Centers Annual Meeting 3Health News:Experimental drug lets B cells live and lymphoma cells die 2Health News:Experimental drug lets B cells live and lymphoma cells die 3Health News:Experimental drug lets B cells live and lymphoma cells die 4Health News:Race has little effect on people's ability to spot family resemblances 2Health News:Lilly Receives 100 Percent Rating on Corporate Equality Index Survey 2Health News:Solos Endoscopy, Inc.'s MammoView(TM) Product Line Receives New Purchase Orders Primarily from Prestigious Teaching Hospitals Across the Country 2Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 2Health News:Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 3
Gerl titanium tying forceps has curved shanks, smooth jaws and 6 mm long tying platform. For 8-0 to 11-0 sutures....
Maumenee tying forceps is straight with concave-convex jaws and has a round handle with guide pin. For 8-0 to 11-0 sutures....
Sinskey tying forcep is very delicate with smooth jaws, curved. For 8-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Medicine Products: